Lexicon Pharmaceuticals | LXRX - Net Income


Lexicon Pharmaceuticals reported $-15.53M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Abbott USD 1.08B 699M Mar/2026
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Akebia Therapeutics USD -12.24M 12.78M Dec/2025
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Coherus Biosciences USD -37.64M 2.11M Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Illumina USD 134M 200M Mar/2026
Insmed USD -163.56M 164.92M Mar/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
J&J USD 5.24B 119M Mar/2026
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Moderna USD -1.34B 517M Mar/2026
Novartis USD 3.16B 747M Mar/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Thermo Fisher Scientific USD 1.65B 313M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
United Therapeutics USD 274.9M 89.4M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024